Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF1-FIH: Safety and PK of MF1 in Healthy Adults and Parkinson's Disease
NCT07666022Phase 1Recruiting
- Sponsor
- University of Shizuoka
- Start
- Jun 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MF1 in Parkinson's disease (PD) (5 arms), sponsored by University of Shizuoka. Primary endpoints: Number of participants with treatment-emergent adverse events and serious adverse events at 12 days, Maximum plasma concentration of MF1 at 5 days and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
MF1
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07666022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07666022.